Tonix Pharmaceuticals logo

Tonix Pharmaceuticals (TNXP) Q1 2026 Earnings

TNXP·Reported May 11, 2026·Before market open

Tonix Pharmaceuticals reported Q1 2026 revenue of $6.9M (+183.2% YoY), beat analyst consensus of $6.1M by $753.0K. Diluted EPS came in at $-2.93 (-3.2% YoY), missed the $-2.54 consensus by $0.39.

Revenue
$6.9Mbeat by $753.0K
Consensus: $6.1M
Diluted EPS
$-2.93missed by $0.39
Consensus: $-2.54
SEC

SEC Filings

Earnings release8-K · 0001999371-26-010487
Quarterly report10-Q · 0001999371-26-010486

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Tonix Pharmaceuticals's Q1 2026 earnings report.

Tonix Pharmaceuticals (TNXP) reported Q1 2026 earnings on May 11, 2026 before market open.

Tonix Pharmaceuticals reported revenue of $6.9M and diluted EPS of $-2.93 for Q1 2026.

Revenue beat the consensus estimate of $6.1M by $753.0K. EPS missed the consensus estimate of $-2.54 by $0.39.

Compared to the same quarter a year prior, revenue grew 183.2% from $2.4M a year earlier and diluted EPS declined 3.2% from $-2.84.

You can read the 8-K earnings release (0001999371-26-010487) and the 10-Q periodic report (0001999371-26-010486) directly on SEC EDGAR. The filing index links above go to sec.gov.